USPSTF adds AIs to list of breast cancer risk-reducing medications

  • USPSTF

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Aromatase inhibitors (AIs) were added to the list of recommended risk-reducing medications that clinicians can offer to postmenopausal women at increased risk for invasive estrogen receptor (ER)-positive breast cancer, provided they are at low risk for adverse medication effects, according to a new draft statement by the US Preventive Services Task Force (USPSTF).

Why this matters

  • The draft recommendation adds a new medication class with a unique safety profile vs previously recommended tamoxifen and raloxifene.
  • No preference is specified.

Key points

  • AIs were found to decrease the incidence of invasive ER-positive breast cancer by 16 events for every 1000 women given the drugs (exemestane or anastrozole) over 5 years of use.
  • AIs have small to moderate harms, including hot flashes, musculoskeletal pain, gastrointestinal symptoms, and possible stroke or fracture.
  • The USPSTF draft does not specify a single cutoff for defining who is at increased risk for breast cancer, but notes that women with at least a 3% risk for breast cancer in the next 5 years are likely to have more benefit than harm.
  • A detailed evidence synthesis accompanies the USPSTF draft recommendation.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit